Johnson & Johnson stock page - price, fundamentals, dividends - iOCharts

JNJ

163.74
-2.01 (-1.21%)
Johnson & Johnson (NYSE, USD)
Healthcare >
Drug Manufacturers-General
Market cap
431.19B
Ent value
525.24B
Price/Sales
5.22
Price/Book
6.55
Div yield
2.59%
Div growth
6.17%
Growth years
58
FCF payout
51.91%
Trailing P/E
29.30
Forward P/E
15.71
PEG
6.11
EPS growth
-0.20%
1 year return
14.38%
3 year return
5.75%
5 year return
7.52%
10 year return
9.89%
Last updated: 2021-10-27

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open165.68
Daily high165.76
Daily low163.31
Daily Volume6.33M
All-time high179.47
1y analyst estimate186.65
Beta0.71
EPS (TTM)5.59
Dividend per share4.24
Ex-div date23 Aug 2021
Next earnings date19 Oct 2021

Downside potential

Loading...
Downside potential data
JNJS&P500
Current price drop from All-time high-8.76%-0.44%
Highest price drop-38.78%-56.47%
Date of highest drop11 Aug 19939 Mar 2009
Avg drop from high-9.49%-11.44%
Avg time to new high19 days12 days
Max time to new high1038 days1805 days

BUSINESS INSIGHT

Segment Revenues ($M)

Loading...
Operations comments

In 21Q1 JNJ COVID-19 Vaccine authorized by U.S. FDA for emergency use

In 21Q1 JNJ Single-Shot COVID-19 Vaccine granted emergency use listing by the World Health Organization

In 21Q1 JNJ Single-Shot COVID-19 Vaccine granted conditional marketing authorization by European Commission

The company has not provided an official guidance for COVID-19 Vaccine revenues and margins for 2021

Geographic Revenues ($M)

Loading...

DIVIDENDS

Dividend yield - 5y

Loading...
Dividend yield data
Dividend per share4.24
Dividend yield2.59%
Payout frequencyQuarterly
Maximum yield3.64%
Average yield2.68%
Minimum yield2.27%
Discount to avg yield-3.57%
Upside potential-3.45%
Yield as % of max yield71.24%

Yield distribution (inverse percentile) - 5y

Loading...
Yield distribution data
Dividend yield2.59%
Current yield distribution68.02%
Yield at 100% (Min)2.27%
Yield at 90%2.46%
Yield at 80%2.53%
Yield at 50% (Median)2.70%
Yield at 20%2.82%
Yield at 10%2.90%
Yield at 0% (Max)3.64%

Dividend per share

Loading...
Dividend per share data
Years of growth58 years
CCC statusDividend Champion
Dividend per share4.24
Payout frequencyQuarterly
Ex-div date23 Aug 2021
EPS (TTM)5.59
EPS (1y forward)10.42
EPS growth (5y)-0.20%
EPS growth (5y forward)4.80%

Dividend growth

Loading...
Please create a free account or log in to access this chart
Dividend growth data
JNJS&P500
DGR MR4.95%7.68%
DGR TTM5.61%-2.66%
DGR 3 years6.23%5.82%
DGR 5 years6.17%6.23%
DGR 10 years6.55%9.64%
DGR 15 years7.88%6.71%
Time since last change announced191 days
EPS growth (5y)-0.20%
EPS growth (5y forward)4.80%

Payout ratio

Loading...
Please create a free account or log in to access this chart
Payout ratio data
EPS coverageFCF coverage
TTM71.23%51.91%
Average52.32%45.73%
Forward40.69%-

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E29.30
Price to OCF18.32
Price to FCF21.36
Price to EBITDA18.17
EV to EBITDA22.14

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales5.22
Price to Book6.55
EV to Sales6.36

FINANCIALS

Per share

Loading...
Per share data
Current share count2.63B
EPS (TTM)5.59
FCF per share (TTM)7.67

Income statement

Loading...
Income statement data
Revenue (TTM)82.58B
Gross profit (TTM)54.19B
Operating income (TTM)19.02B
Net income (TTM)14.71B
EPS (TTM)5.59
EPS (1y forward)10.42

Margins

Loading...
Margins data
Gross margin (TTM)65.62%
Operating margin (TTM)23.03%
Profit margin (TTM)17.82%

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash12.67B
Net receivables14.94B
Total current assets52.53B
Goodwill35.69B
Intangible assets51.11B
Property, plant and equipment18.37B
Total assets172.56B
Accounts payable37.58B
Short/Current long term debt33.61B
Total current liabilities40.93B
Total liabilities106.72B
Shareholder's equity65.83B
Net tangible assets-20.96B

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)23.54B
Capital expenditures (TTM)3.35B
Free cash flow (TTM)20.19B
Dividends paid (TTM)10.48B

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity23.25%
Return on Assets8.41%
Return on Invested Capital14.93%
Cash Return on Invested Capital20.49%
COMPANY DETAILS
JNJ (Johnson & Johnson) company logo
Marketcap
431.19B
Marketcap category
Large-cap
Description
Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; smoking cessation products under the NICORETTE brand; and acid reflux products under the PEPCID brand. This segment also provides women's health products, such as sanitary pads and tampons under the STAYFREE, CAREFREE, and o.b. brands; wound care products comprising adhesive bandages under the BAND-AID brand; and first aid products under the NEOSPORIN brand. The Pharmaceutical segment offers products in various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. The Medical Devices segment provides electrophysiology products to treat cardiovascular diseases and neurovascular care products to treat hemorrhagic and ischemic stroke; orthopaedics products in support of hips, knees, trauma, spine, sports, and other; advanced and general surgery solutions that focus on breast aesthetics, ear, nose, and throat procedures; and disposable contact lenses and ophthalmic products related to cataract and laser refractive surgery under the ACUVUE brand. The company markets its products to general public, and retail outlets and distributors, as well as distributes directly to wholesalers, hospitals, and health care professionals for prescription use. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.
Employees
134500
SEC filings
CEO
Alex Gorsky
Country
USA
City
New Brunswick
Stock type
Common stock
CCC status
Dividend Champion
Dividend Frequency
Quarterly
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
Dr. Ben Weston, Milwaukee COVID-19 Emergency Operations Center Medical Director, talks about the process of approving the COVID-19 vaccine for children and the global fight against COVID-19.
October 27, 2021
The United States has administered 416,154,424 doses of COVID-19 vaccines in the country as of Wednesday morning and distributed 507,637,305 doses, the U.S. Centers for Disease Control and Prevention ...
October 27, 2021
Novavax CEO Stanley Erck joins Yahoo Finance to discuss the company's filing for vaccine authorization in the UK, plans to seek approval from the FDA, and how supply chain disruption has affected the ...
October 27, 2021
The healthcare sector is expected to witness substantial earnings growth of 17.5% in the third quarter.
October 27, 2021
Johnson & Johnson (NYSE:JNJ) received a lot of attention from a substantial price movement on the NYSE over the last few months. Some share price movements can give investors a better opportunity to e...
October 27, 2021
University Hospital CEO and Fmr. Health Commissioner of New Jersey Dr. Shereef Elnahal joins the Yahoo Finance Live panel to discuss the latest outlook for COVID-19 as health officials continue to deb...
October 26, 2021
The United States has administered 415,012,026 doses of COVID-19 vaccines in the country as of Tuesday morning and distributed 504,584,715 doses, the U.S. Centers for Disease Control and Prevention sa...
October 26, 2021
It's the sixth year in a row that the company leader has placed on the list, which honors 50 women at the top of their industries.
October 26, 2021
Taylor Carmichael (Novavax): Novavax's COVID-19 vaccine is still not on the market anywhere, which has made the stock a real wild ride for investors. The vaccine specialist started off 2020 so small ...
October 26, 2021
Next page